SCHEMBL14166018

SCHEMBL14166018

O=C(O)N(Cc1ccccc1)c1cccc(O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 2/20 0.57
RAB9A P51151 4/20 0.52
NPC1 O15118 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HTT P42858 3/20 0.52
PAX8 Q06710 2/20 0.52
JAK2 O60674 1/20 0.52
GLA P06280 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
OPRK1 P41145 3/20 0.49
OPRM1 P35372 2/20 0.49
OPRD1 P41143 2/20 0.49
TSPO P30536 1/20 0.47
GAA P10253 1/20 0.47
TSHR P16473 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL5435104 0.93 PDK1 (0.51) PDK1RAB9ANPC1ALDH1A1HTT
SCHEMBL28986105 0.84 NPC1 (0.61) PDK1RAB9ANPC1ALDH1A1HTT
SCHEMBL1927016 0.83 ALDH1A1 (0.69) PDK1RAB9ANPC1ALDH1A1HTT
SCHEMBL1925718 0.81 RAB9A (0.51) PDK1RAB9ANPC1ALDH1A1HTT
SCHEMBL6827496 0.81 RAB9A (0.53) RAB9ANPC1ALDH1A1HTTPAX8
SCHEMBL1924845 0.81 RAB9A (0.55) PDK1RAB9ANPC1ALDH1A1HTT
SCHEMBL1924742 0.81 RAB9A (0.76) RAB9ANPC1ALDH1A1HTTPAX8
SCHEMBL10348190 0.81 ALDH1A1 (0.59) PDK1RAB9ANPC1ALDH1A1HTT
SCHEMBL5088886 0.81 ALDH1A1 (0.46) PDK1RAB9ANPC1ALDH1A1HTT
SCHEMBL1259310 0.80 PDK1 (0.58) PDK1RAB9ANPC1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2718280-B1 COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY CHIESI FARMA SPA (IT) 2015-09-16 EP disclosed
US-8877774-B2 Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity CHIESI FARMACEUTICI S.P.A. (IT) 2014-11-04 US disclosed
EP-2718280-A1 COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY Chiesi Farmaceutici S.p.A. (IT) 2014-04-16 EP disclosed
US-20130045169-A1 COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY CHIESI FARMACEUTICI S.P.A. (IT) 2013-02-21 US disclosed
WO-2012168359-A1 COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY CHIESI FARMACEUTICI S.P.A. (IT) 2012-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045169-A1 COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY ADRB2, ADRB1, ADRA2B PDK1 4080/4885RAB9A 2495/4885NPC1 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.